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ABSTRACT
PALB2 is essential for BRCA2 anchorage to nuclear
structures and for homologous recombinational
repair of DNA double-strand breaks. Here, we
report that the N-terminal coiled-coil motif of
PALB2 regulates its self-association and homolo-
gous recombination. Monomeric PALB2 shows
higher efficiency to bind DNA and promotes
RAD51 filament formation with or without the inhibi-
tory effect of Replication Protein A. Moreover,
overexpression of the PALB2 coiled-coil domain
severely affects RAD51 loading to DNA damage
sites suggesting a competition between PALB2
self-interaction and PALB2–BRCA1 interaction. In
the presence of DNA damage, the switch between
PALB2–PALB2 and PALB2–BRCA1 interactions
allows the activation of HR. Controlling HR via
PALB2 self-interactions could be important to
prevent aberrant recombination in normal condi-
tions and activate DNA repair when required.
INTRODUCTION
Cellular DNA double-strand breaks (DSBs) are amongst
the most dangerous DNA damage. They can result from
genotoxic agents or stalled replication forks (1).
Homologous recombination (HR) is the major pathway
to repair DBSs during late S phase to G2 phase of the cell
cycle, leading to faithful repair of DNA damage using the
sister chromatid as the repair template (1,2). The central
step of HR is orchestrated by the RAD51 recombinase
using resected DNA DSBs to invade a homologous
duplex DNA leading to displacement loop (D-loop) (3).
The recombination mediator BRCA2 transports RAD51
to the nucleus (4), promotes assembly of RAD51 onto
single-stranded DNA (ssDNA) (5) and stimulates
RAD51 during the invasion step of HR (3).
PALB2 (partner and localizer of BRCA2) was identified
as a novel interactor of BRCA2, crucial for its localization
to chromatin and recruitment to DSBs (6). The PALB2
gene is localized on chromosome 16p12.2 and encodes a
protein of 1186 amino acids (7). Heterozygous mutations
in PALB2 are associated with predisposition to breast and
pancreatic cancers (8–10). Homozygous or biallelic muta-
tions lead to Fanconi Anemia (11,12), an inherited
genomic instability disorder caused by mutations in
genes regulating replication-dependent removal of inter-
strand DNA crosslinks (13).
PALB2 links BRCA1 and BRCA2 to promote efficient
DNA repair by HR (6,14–16). In the absence of PALB2,
recruitment of BRCA2 and RAD51 to the DSBs cannot
proceed (6,12). PALB2 interacts with BRCA1 by its
N-terminal coiled-coil domain (14–16) and with BRCA2
via its WD40 domain at the C-terminal (6,17). The
coiled-coil domain and the WD40 domain of PALB2 are
both important for optimal HR (12,14,16). A third domain
recently characterized named ChAM (Chromatin-
Association Motif), located at the center of the protein, is
required for PALB2 chromatin localization (18).
PALB2-deficient cells expressing PALB2 without one of
these three domains show a defect for RAD51 foci forma-
tion at DSBs and a high sensitivity to the interstrand
crosslinking agent mitomycin C (12,18,19), which causes
replication fork collapse and DSB formation (13). The
coiled-coil domain is also responsible for oligomerization
of PALB2 (19) but the function of the PALB2
self-interaction is complex and poorly understood.
Recently, it has been shown that purified full-length
PALB2, like BRCA2, binds DNA and interacts directly
with RAD51 (20–24). PALB2 promotes the RAD51
filament formation onto the ssDNA (20) and stimulates
RAD51 for the strand invasion to form the D-loop
structure (20,21). This new discovery demonstrates that
PALB2 is not purely a localizer of BRCA2, but also an
important regulator of RAD51 activity. In this article, we
analyzed the function of PALB2 oligomerization to
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understand its role in regulating RAD51 and DNA
recombination.
MATERIALS AND METHODS
Cells
HEK293T and HeLa cells were maintained in DMEM
supplemented with 10% fetal bovine serum and 1% peni-
cillin/streptomycin and transfected, with calcium phos-
phate and Effectene (Qiagen), respectively.
DNA constructs
PALB2 DNA constructs were derived from PCR ampli-
fication of PALB2 cDNA in pOZC vector (6) and cloned
as a Flag-tagged or as a Myc-tagged version into pcDNA3
(Invitrogen), or a derivative of pFASTBAC1 (Invitrogen)
with His-/Flag-tag. PALB2 truncations were cloned by
PCR amplification in pcDNA3 with a Myc-tag or
GFP-tag in N-terminal or in pGEX6P2 (GE Healthcare)
with a GST-tag or GST-/His-tag.
Antibodies
Commercial antibodies used were anti-PALB2 polyclonal
antibody (Bethyl), anti-BRCA1 monoclonal antibody
(17F8, GeneTex), anti-BRCA1 polyclonal antibody
(Millipore), anti-BRCA2 monoclonal antibody (OP95,
Calbiochem), anti-RAD51 monoclonal antibody (14B4,
Novus), anti-RAD51 polyclonal antibody (Santa-
Cruz), anti-Histidine (Clontech), anti-Myc monoclonal
antibody (Cell Signaling) and anti-Flag monoclonal
antibody (Sigma). Rabbit polyclonal anti-GST antibody
was generated by immunizing rabbits with recombinant
GST which was expressed and purified from Escherichia
coli. For immunofluoresence, rabbit polyclonal
anti-PALB2 antibody was generated by immunizing
rabbits as previously described (6).
Protein purification
RAD51, or RPA were purified as described (25,26).
PALB2 or PALB21–40 were purified from baculovirus-
infected Sf9 cells. One-liter of Sf9 insect cells (1 106
cells/ml) were infected with baculovirus for 3 days at
27C. Cells were harvested, centrifuged (1000 rpm/
10min), and the cell pellet was resuspended in 40ml of
Flag buffer (50mM Tris–HCl pH 7.5, 150mM NaCl,
2mM EDTA, 1mM DTT, 0.25% Triton X-100 and
10% glycerol) containing protease inhibitors (Roche).
The suspension was lysed using a Dounce homogenizer
(10 strokes), sonicated three times 30 s (50% output),
and then homogenized a second time. An amount of
15U/ml of Benzonase and 1mM of MgCl2 were added
for 1 h at 4C and insoluble material was removed by cen-
trifugation (35 000 rpm for 40min). Then, 300 ml of M2
anti-Flag affinity gel (Invitrogen) was added to the
soluble extract for 3 h at 4C. The beads were washed
twice with washing buffer (50mM Tris–HCl pH 7.5,
250mM NaCl, 2mM EDTA, 1mM DTT, 0.25% Triton
X-100 and 10% glycerol) and incubated 30min with
washing buffer supplemented with 5mM ATP and
15mM MgCl2. After two additional washes with Elution
Flag buffer (50mM Tris–HCl pH 7.5, 150mM NaCl,
0.25% Triton X-100 and 10% glycerol), proteins were
eluted twice in one volume of beads with Elution Flag
buffer and 500 mg/ml of 3X-Flag peptide for 45min at
4C. The eluted proteins were pooled and added in 5ml
of T5 buffer (20mM NaHPO4 pH 7.4, 500mM NaCl,
10% glycerol, 0.02% Triton, 5mM Imidazole). Then,
300 ml of Talon resin (Clontech) was added and the
mixture was incubated for 2 h at 4C. Following centrifu-
gation (1000 rpm, 30 s), the Talon resin was washed three
times with T5 buffer. Proteins were eluted with 500mM
Imidazole in Talon buffer (300ml) and dialyzed in the
storage buffer (20mM Tris–Acetate, pH 8.0, 200mM
KOAc, 10% glycerol, 1mM EDTA, 0.5mM DTT) and
stored in aliquots at 80C.
GST-protein purification
Protein truncations (GST-PALB2-T1, PALB2-T1-His and
PALB2-T11–40-His) were purified from 1 l of E. coli
BL21(DE3) RP (Stratagene), grown at 37C in Luria
Broth medium supplemented with 100 mg/ml ampicillin,
and 25 mg/ml chloramphenicol. At OD600=0.4, 0.1mM
IPTG was added to the culture and incubated at 15C
overnight (16 h). The cell pellet was resuspended in 40ml
of GST buffer (10mM Na2HPO4, 2mM KH2PO4,
297mM NaCl, 2,7mM KCl, 1mM EDTA and 1mM
DTT) containing protease inhibitors (Roche). The suspen-
sion was lysed using a Dounce homogenizer (10 strokes),
sonicated three times 30 s, and then homogenized a second
time. Insoluble material was removed by centrifugation
(35 000 rpm for 40min). One-milliliter of Glutathione
Sepharose (GE Healthcare) was added to the supernatant
and incubated during 2 h at 4C. Then, beads were washed
three times with GST washing buffer (10mM Na2HPO4,
2mM KH2PO4, 500mM NaCl, 2.7mM KCl, 1mM
EDTA and 1mM DTT) and incubated 30min in GST
washing buffer complemented with 5mM ATP and
15mM MgCl2. GST-PALB2-T1 was eluted with GST
buffer+25mM glutathione during 2 h at 4C.
PALB2-T1-His and PALB2-T11–40-His were eluted by
cleavage with PreScission protease (60U/ml GE
Healthcare) overnight at 4C in PreScission buffer
(50mM Tris–HCl pH 7.4, 150mM NaCl, 1mM EDTA,
1mM DTT and 0.05% Tween 20). All eluted proteins
were dialyzed in storage buffer (20mM Tris–Acetate, pH
8.0, 200mM KOAc, 1mM EDTA, 0.5mM DTT and 10%
glycerol) and stored at 80C.
GST pull-downs
Purified GST-PALB2-T1 (250 ng) was incubated with
250 ng of purified PALB2-T1-His or PALB2-T11–40-His
for 25min at room temperature in 100 ml of GSTB buffer
(20mM KPO4 pH 7.4, 250mM KCl, 0.5mM EDTA, 10%
Glycerol, 1mM DTT, 0.5% NP-40 and 1mg/ml bovine
serum albumin (BSA)), then 25 ml of Glutathione
Sepharose beads (GE Healthcare) and 400 ml of GSTB
buffer were added for 20min at room temperature.
Beads were washed four times with GSTB buffer
without BSA and eluted with 40 ml of Laemmli buffer.
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Proteins were visualized by western blotting using the
indicated antibodies.
Co-immunoprecipitations and GFP pull-down
HEK293T cells were transfected with the indicated
PALB2 constructs and treated (when indicated) with
2mM of hydroxyurea (HU) for 20 h. Then, cells were re-
suspended in lysis buffer (50mM Tris–HCl, pH 7.5,
150mM NaCl, 0.5% NP-40) containing protease and
phosphatase inhibitors (PMSF (1mM), aprotinin (0.019
TIU/ml), leupeptin (1 mg/ml), NaF (5mM) and Na3VO4
(1mM)), incubated for 30min on ice, and lysed by sonic-
ation. Insoluble material was removed by high-speed
centrifugation (13 000 rpm at 4C) and each immuno-
precipitation (IP) was carried out using soluble protein
extract in 1ml of lysis buffer. Fifty microliters of
anti-Flag M2 affinity gel (Sigma) or 15 ml of
GFP-Trap-A beads (Chromotek) and 70U of DNase I
(when indicated) were added and incubated for
2 h30min at 4C. Beads were washed three times with
washing buffer (50mM Tris–HCl pH 7.5, 250mM NaCl,
0.5% NP-40) and proteins were eluted with 60 ml of
Laemmli buffer. Proteins were visualized by western
blotting using the indicated antibodies.
IPs from purified proteins were performed as follows.
Purified Flag-PALB2-His or Flag-PALB21–40-His
(250 ng) and RAD51 (500 ng) were incubated in 100 ml of
GSTB buffer for 20min at 37C. Then 20 ml of anti-Flag
M2 affinity gel (Sigma) was added and incubated for
20min at room temperature. Beads were washed three
times with GSTB buffer without BSA and proteins were
eluted with 40 ml of Laemmli buffer and visualized by
western blotting using the indicated antibodies.
Gel filtration
HEK293T cells were transfected with Flag-PALB2 or
Flag-PALB21–40 constructs. Cells were resuspended in
lysis buffer (20mM Tris–HCl pH 7.5, 500mM NaCl,
1mM EDTA and 0.5% Triton X-100) containing
protease and phosphatase inhibitors (PMSF (1mM),
aprotinin (0.019 TIU/ml), leupeptin (1mg/ml), NaF
(5mM) and Na3VO4 (1mM)), incubated for 5min on
ice, and lysed by sonication. Then 150U/ml of Benzonase
and 5mM MgCl2 were added and the total extract was
incubated for 30min at 4C. Insoluble material was
removed by high-speed centrifugation (13 000 rpm at
4C). Soluble extracts (2mg) were analyzed on an FPLC
Explorer 10 system fitted with a Superose 6 column 10/300
GL (GE Healthcare) equilibrated in lysis buffer and 1mM
PMSF. Fractions (500ml) were collected and analyzed by
western blotting with a Flag antibody (Sigma). The size of
PALB2 or PALB21–40 was determined by comparison
with gel filtration standards (250 mg; bovine thyroglobulin
(670kDa), bovine gamma globulin (158kDa), chicken ov-
albumin (44 kDa), horse myoglobin (17 kDa) and vitamin
B12 (1.35 kDa)).
DNA-binding assays
Reactions (10ml) contained 32P-labeled DNA oligonucleo-
tides (100 nM nucleotides, Supplementary Table I) and
PALB2 or PALB21–40 in binding buffer (25mM MOPS
pH 7, 40mM KOAc, 40mM KCl, 0.2% Tween 20 and
1mM DTT). Reaction mixtures were incubated at 37C
for 15min and analyzed on a 8% TBE1/acrylamide gel
(150V/2 h30 at 4C).
D-loop assays
32P-labeled linear DNA with 30-tailed DNA was generated
as previously described (20). 32P-labeled 30-tailed DNA
substrate (1 mM nucleotides, Supplementary Table I) was
incubated for 5min with the indicated concentration of
RAD51 and PALB2 in 9 ml of 50mM MOPS pH 7,
60mM KOAc, 250 mM CaCl2, 300 mM EDTA, 1mM
DTT, 2mM ATP and 100 mg/ml BSA. CsCl-purified
pPB4.3 replicative form I DNA (300 mM) was added and
the reaction was incubated for 1 h 30min followed by
the addition of one-fifth volume of stop buffer (10%
SDS and 10mg/ml proteinase K) and 20min incubation
at 37C. Labeled DNA products were analyzed by elec-
trophoresis through a 0.8% TBE1/ agarose gel, run at
65 V, dried onto DE81 filter paper and visualized by
autoradiography.
Biotin pull-down assay
Magnetic beads containing 50-biotinylated ssDNA poly
dT 83-mer (corresponding to the final concentration of
1 mM nucleotide) were pre-incubated with a blocking
buffer (25mM MOPS pH 7, 40mM KCl, 0.2% Tween
20, 1mM DTT and 10mg/ml BSA) for 20min at 37C.
The beads were captured with the magnetic particle sep-
arator, washed once with DC buffer (25mMMOPS pH 7,
40mM KCl, 0.2% Tween 20, 1mM DTT, 1mg/ml BSA,
2mM ATP and 0.5mM MgCl2) and resuspended in 16 ml
of this buffer. 100 nM of RPA was added and the reaction
was incubated for 5min at 37C. Then, 400 nM of RAD51
was added 5min at 37C. The indicated concentration
of PALB2 protein was added for 10min at 37C in
20 ml. The beads were captured, washed twice with 40 ml
of washing buffer (25mMMOPS pH 7, 40mMKCl, 0.2%
Tween 20, 1mM DTT, 2mM ATP and 0.5mM MgCl2),
and 15 ml of Laemmli buffer 1 was added followed
by heating 5min at 95C. The beads were captured and
the supernatants were loaded on a SDS-PAGE 8% poly-
acrylamide gel. The gel was stained with Sypro Ruby
(Invitrogen) and visualized by UV.
Immunofluorescence
Hela cells were transfected with PALB2-T1-Myc or
PALB2-T11–40-Myc, treated with 2mM of HU for 16–
18 h and fixed with 2% paraformaldehyde in PBS
for 10min, washed with TBS and fixed with cold methanol
(20C) for 5min. Next, cells were permeabilized with
PBS containing 0.2% Triton X-100 for 5min and
washed three times 5min each with TBS. Then, cells
were quenched with 0.1% Sodium Borohydride for
5min, washed once with TBS, blocked in PBS containing
10% goat serum and 1% BSA for 1 h and incubated in the
primary antibody diluted in PBS 1% BSA for 2 h at room
temperature. Coverslips were washed three times for
10min with TBS before 1 h incubation with the
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appropriate secondary antibody conjugated to a
fluorophore (Alexa Fluor 488 (green) and Alexa Fluor
568 (red) from Invitrogen). Cells were rinsed again three
times for 10min with TBS. Coverslips were mounted onto
slides with PBS-glycerol (90%) containing 1mg/ml
paraphenylenediamine and 0.2mg/ml of 4,
6-diamidino-2-phenylindole (DAPI).
Immunofluorescence for PALB2 and BRCA1 visualiza-
tion was performed as follows. Hela cells were transfected
with PALB2-T1-GFP and were treated with 2mM of HU
for 16–18 h. Then, Hela cells were incubated for 5min with
a pre-extraction buffer (10mM PIPES pH 6.8, 100mM
NaCl, 300mM sucrose, 3mM MgCl2, 1mM EGTA and
0.2% Triton X-100), fixed with 3.7% paraformaldhyde in
PBS for 20min, washed with PBS and fixed with cold
methanol (20C) for 20min. Then, cells were washed
with PBS, treated 30 s with cold acetone (4C), washed a
second time with PBS and blocked in PBS containing 3%
BSA for 30min before incubating with the primary
antibody diluted in PBS 3% BSA for 2 h at room tempera-
ture. Coverslips were washed three times for 5min with
PBS before 1 h incubation with the appropriate secondary
antibody conjugated to a fluorophore (Alexa Fluor 488
(green), Alex Fluor 568 (red) and/or Alexa Fluor 647 (far
red) from Invitrogen) and mounted as described above.
RESULTS
Identification of a unique PALB2 self-interaction domain
To better understand the role of PALB2 oligomerization
in HR, and to prove that PALB2 has not more than
one dimerization domain, we performed a detailed struc-
ture function analysis. To monitor PALB2 self-
association, we co-expressed full-length Myc-PALB2 and
Flag-PALB2 or Flag-PALB2 internal deletion mutants
spanning the entire coding sequence (Figure 1A,
PALB2T1–T5) followed by anti-Flag IP. A Myc-PALB2/
Flag-PALB2 co-complex was detected (Figure 1B, lane 2)
confirming dimerization of PALB2. The dimerization of
PALB2 was lost when the N-terminal domain (amino
acids 1–200) was removed (lane 3). To detect whether
the evolutionary conserved coiled-coil motif in the
N-terminal domain of PALB2 (amino acids 1–40) allows
self-interaction, co-IP assays were performed with Myc-
PALB2 and Flag-PALB21–40 (Figure 1A and C).
Removal of the coiled-coil domain from the wild-type
protein completely abrogated self-interaction (Figure 1C,
compare lanes 2 and 3). This result was confirmed using
size-exclusion chromatography where PALB2 eluted as
two major peaks (Figure 1D). The peak A (fractions
21–25) eluted close to the predicted monomer size of
Flag-PALB2-His (135 kDa), whereas, the peak B (frac-
tions 13–15) most likely corresponds to a mixture of
PALB2 multimers. Unlike wild-type PALB2,
PALB21–40 was eluted in only peak A, indicative of the
monomeric form (Figure 1D).
BRCA1 and PALB2 interact via their coiled-coil
domains (14–16). It has been reported that the deletion
of the first forty amino acids of PALB2 completely abro-
gates PALB2 foci formation (19). Furthermore expressing
PALB2 without the coiled-coil domain leads to high sen-
sitivity to mitomycin C and HR defects (19). Taken
together, these results show that (i) the interaction
between PALB2 and BRCA1 is critical for HR repair
and (ii) suggest a competition between PALB2–PALB2
and BRCA1–PALB2 interactions, which may allow a
regulation of PALB2 mediator activity in cells.
Enhanced DNA binding by monomeric PALB2
As it was difficult to separate PALB2 self-interactions and
BRCA1–PALB2 functions in vivo, we resorted to in vitro
assays to further dissect the function of the monomeric or
dimeric form of PALB2. PALB2 binds DNA (20,21) using
two distinct DNA-binding regions (20). To assess whether
PALB2 dimerization is important for its DNA-binding
activity, we purified wild-type PALB2 and a mutant
PALB2 deleted of its coiled-coil motif (Supplementary
Figure S1A). PALB21–40 showed about 5-times
stronger affinity for ssDNA than PALB2 (Figure 2A).
In addition, PALB2 binding to DNA leads to the forma-
tion of several bands in the gel suggesting multimeric
forms of the protein bound to DNA whereas only one
band was observed for PALB21–40 at the same size as
the lowest band for wild-type PALB2. This result
suggests that the dimerization of PALB2 could affect the
accessibility of both DNA-binding domains of PALB2 to
ssDNA. Furthermore, a switch between the multimeric to
monomeric form of PALB2 could control PALB2 loading
on DSBs by regulating its binding on DNA.
We have previously shown that PALB2 stimulates
RAD51 in D-loop formation (20), a key step of HR. We
monitored the activation of RAD51 by PALB2, in condi-
tions where RAD51 saturates the ssDNA substrate prior
to invasion into a homologous DNA (Figure 2B). In these
conditions, RAD51 is in a stable form on tailed DNA
prior to DNA invasion, which allows us to discriminate
RAD51 activation from the formation of RAD51 nucleo-
protein filaments. In the absence of PALB2, little ssDNA
was converted into a D-loop by RAD51 (Figure 2B, lane
2), whereas PALB2 strongly stimulated this reaction (lane
3). The stimulation was dependent on ATP/CaCl2 and
supercoiled DNA (lanes 4–5). Surprisingly, PALB21–40
showed a similar effect on RAD51 (lanes 6). This result
indicates that multimerization of PALB2 has no effect on
RAD51 D-loop activity.
Monomeric PALB2 stimulates RAD51 filament formation
The similar effect of PALB2 and PALB21–40 on
RAD51-mediated D-loop formation prompted us to in-
vestigate whether the deletion of the coiled-coil domain
could impact on other key steps of HR. For instance,
prior to strand invasion, the ssDNA-binding protein
RPA must be displaced from the single-strand tail of the
newly resected DSB to allow RAD51 filament formation.
Such function is accomplished by BRCA2 or PALB2 re-
combination mediators to overcome the inhibitory effect
of RPA and allow RAD51 to nucleate on the ssDNA to
promote the pre-synaptic filament assembly (20,23). In the
presence of RPA, RAD51 loading on ssDNA was strongly
inhibited (Figure 3A, lane 2). PALB2 alleviated the
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inhibitory effect of RPA (Figure 3A, lanes 3–5 and
Supplementary Figure S2A) to promote RAD51 filament
formation. Notably, PALB21–40 was much more efficient
to promote RAD51 nucleoprotein filament formation
than PALB2 on ssDNA protected by RPA (Figure 3A,
lanes 6–8 and Supplementary Figure S2A). This effect was
not due to enhanced RAD51 binding by PALB21–40 as
both PALB2 and PALB21–40 interacted equivalently
with RAD51 (Supplementary Figure S2B). As observed
with Brh2 or LiBRCA2, conserved but smaller BRCA2
orthologs in Ustilago Maydis or Leishmania infantum,
RPA was still bound to the ssDNA beads although the
inhibitory effect of RPA on RAD51 was removed (27,28).
This might occur through protein–protein interactions as
RPA binds RAD51 (29) or that PALB2 displaces RPA on
the ssDNA allowing RAD51 to form a nucleoprotein
filament. In the absence of ATP and magnesium,
RAD51 still displays a weak DNA-binding activity
(Figure 3B, compare RAD51 ATP/MgCl2 to RAD51
+ATP/+MgCl2). We observed that PALB2
1–40 promotes
the loading of RAD51 on ssDNA better than PALB2, in
the absence (Figure 3B, lanes 1–3) or in the presence of
RPA (lanes 4–6). Taken together, these results imply that
the monomeric form of PALB2 has enhanced activity to
stimulate RAD51 DNA binding and filament formation.
The N-terminal coiled-coil of PALB2 acts as a dominant
negative protein
In cells, PALB2 colocalizes with RAD51 after HU treat-
ment (Supplementary Figure S3A) and is required for its
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localization at DSBs (6). Our results suggest that the
monomeric form of PALB2 possesses higher activity
compared to the multimeric form. If it was the case,
overexpression of the N-terminal domain (PALB2-T1)
may disrupt the balance between monomeric PALB2
(elevated activity) and dimeric PALB2 (basal activity) by
forming a PALB2–PALB2-T1 complex leading to a sub-
sequent decrease in HR (Supplementary Figure S3B). We
overexpressed GFP-PALB2-T1 and GFP-PALB2-T11–40
in HeLa cells and monitored RAD51 foci formation. The
expression of GFP-PALB2-T1, strongly affected the local-
ization of RAD51 to DSBs induced by DNA replication
block whereas GFP-PALB2-T11–40 did not affect
RAD51 foci formation (Figure 4A). Quantification of
the DNA damage-induced RAD51 foci showed a 10-fold
decrease in cells expressing the wild-type N-terminal
fragment compared to those expressing the deletion
mutant (Figure 4B). Because the GFP-tag could interfere
with the N-terminal domain of PALB2, we have con-
firmed this result by expressing the PALB2-T1 coupled
with the smaller tag Myc (Supplementary Figure S4A
and B). Loss of RAD51 foci cannot be explained by an
effect on the cell cycle induced by the overexpression of
the T1-PALB2 since cell-cycle progression was not affected
(Supplementary Figure S4C). Moreover, we have con-
firmed in vivo with a DNase I treatment or in vitro with
purified proteins that N-terminal PALB2-T1 fragment
self-interacts and PALB2-T11–40 does not (Supplemen-
tary Figure S5A–C).
To better define the role of PALB2 self-interaction in
RAD51 foci formation, we overexpressed GFP-PALB2-
T1 in Hela cells. Cells expressing GFP-PALB2-T1 were
strongly affected for RAD51 foci formation but also for
PALB2 foci formation, whereas untransfected cells show a
normal colocalization between PALB2 and RAD51 at
DSBs (Figure 4C, compare GFP positive to negative
cells). Importantly, the expression of GFP-PALB2-T1
did not affect BRCA1 foci formation (Figure 5A). In
this immunofluorescence experiment, a pre-extraction
has been performed before fixation of the cells. This
pre-extraction is crucial for the visualization of PALB2
foci. This, however, results in a loss of staining of
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the nuclear soluble T1–PALB2–GFP (Supplementary
Figure S3C) explaining the difference of staining
between Figure 4A and Figure 4C–5A.
PALB2 foci formation is essential for RAD51 localiza-
tion to DSBs via BRCA2 (6,12). On the other hand,
PALB2 localization appears to be dependent on its
interaction with BRCA1 (15,16). To further define the
role of PALB2–BRCA1 interaction, we co-expressed
GFP-PALB2-T1 and Flag-PALB2T2. The expression
of PALB2T2 allows us to separate the overexpressed
from endogenous PALB2 by western blotting. Note that
the T2 domain is not required for PALB2 functionality
Figure 3. Stimulation of RAD51 filament formation by monomeric PALB2. (A) Left: schematic of RPA displacement assay. Right: RPA bound to a
ssDNA oligonucleotide prevents RAD51 assembly (lane 2) whereas addition of PALB2 or PALB21–40 (15, 30 and 50 nM) stimulates RAD51
filament formation in presence of RPA (lanes 3–8). Bottom: quantification of the results. The Y-axis represents the ratio between the values obtained
for RAD51 filament in the presence of RPA and PALB2 or PALB21–40 divided by the value obtained for RAD51 filament with ATP and
magnesium without RPA (set at 100%). (B) Left: RPA displacement assay in the absence of ATP and MgCl2. Right: quantification of the
results. The Y-axis represents the ratio between the values obtained for RAD51 filament in the absence of ATP/MgCl2 with or without RPA
and PALB2 or PALB21–40 divided by the value obtained for RAD51 filament with ATP and magnesium without RPA (set at 100%).
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in vivo (12). Co-IP of endogenous PALB2 and endogenous
BRCA1 with PALB2T2 was decreased by the over-
expression of GFP-PALB2-T1 but not when the
coiled-coil motif was missing. In contrast, the interactions
with BRCA2 and RAD51 were not affected (Figure 4D).
These results suggest that the overexpression of the
coiled-coil domain of PALB2 prevent PALB2 from inter-
acting with BRCA1. However, following DNA damage,
BRCA1 must be able to compete with PALB2–PALB2
interactions, to generate a PALB2–BRCA1 complex ef-
fective for DNA repair.
To verify this possibility, we scrutinized whether
purified BRCA1 coiled-coil domain (Supplementary
Figure S5D) was able to compete with purified PALB2
coiled-coil (PALB2-T1) to interact with the full-length
PALB2 (Figure 5B). To do so full-length Flag-PALB2
was incubated with GST-BRCA1-CC (GST fusion to
the coiled-coil region of BRCA1), GST-PALB2-T1 or
both (lanes 3–5) followed by IP analysis. First, we
observed an interaction between GST-BRCA1-CC and
Flag-PALB2 (lane 3), and as described before, an inter-
action between Flag-PALB2 and GST-PALB2-T1 (lane 4)
was detected. However, when GST-BRCA1-CC was
added to the reaction, the amount of Flag-PALB2/GST-
PALB2-T1 co-complex was reduced (lane 5). Conse-
quently, the coiled-coil region of BRCA1 can disrupt
PALB2–PALB2 interactions. This result was corrobo-
rated in another independent experiment. Flag-PALB2
was incubated with GST-BRCA1-CC for 5–20min,
followed by the addition of GST-PALB2-T1. At 10 and
20min, GST-BRCA1-CC completely abrogated the
Flag-PALB2/GST-PALB2-T1 co-complex observed at
5min (compare lanes 7–9). Altogether, these results indi-
cate that in vivo PALB2 self-interaction which inhibits
DNA recombination, can be suppressed by the interaction
with BRCA1. In support of this, BRCA1 interacts more
strongly with PALB2 after DNA damage (Figure 5C). We
observed an increase of 60–70% of PALB2–BRCA1 inter-
action when cells were treated with HU.
DISCUSSION
PALB2 was discovered in 2006 and rapidly established as
a tumor suppressor. It was also characterized as a linker
protein between BRCA1 and BRCA2 as cells treated with
PALB2 siRNAs, but not a control siRNA, abolished the
association between BRCA1 and BRCA2 (16). However,
the function of PALB2 domains in HR remains poorly
explored. The PALB2 structure shows an unusual level
of complexity. It bears two DNA-binding domains,
two RAD51 interacting regions, a ChAM domain, a
seven-bladed WD40-type b-propeller, and a self-
interaction domain (Figure 6A). Our results provide
mechanistic insights into the function of PALB2 through
its coiled-coil motif. It is well known that coiled-coil
domains mediate protein–protein interactions, typical
examples in the recombination field being RAD50
(30,31) and Hop2-Mnd1 (32). In previous studies, Sy
and colleagues generated alanine substitution mutations
in the heptad-helical coiled-coil arrangement on PALB2
(corresponding to residues K14A, L21A, Y28A, L35A
and E42A). The interactions between BRCA1 and the
PALB2 L21A, Y28A, or L35A mutants were largely abol-
ished. Moreover, the latter mutants were defective for HR
(14). In another study by the Andreassen group, two point
mutants (L21P and L24P) were generated in the PALB2
coiled-coil domain, and the mutants did not restore resist-
ance to mitomycin C in EUFA1341 fibroblasts, compared
to full-length PALB2 (15). Using site directed mutagen-
esis, we were unsuccessful to fully dissociate BRCA1
binding to PALB2–PALB2 binding, suggesting a compe-
tition for binding to the same sites in the coiled-coil
region. Therefore, we examined whether we could dissect
the regulation of PALB2–PALB2 to BRCA1–PALB2
interactions using alternative biochemical and cellular
approaches.
Our data suggest sequential protein–protein inter-
actions to activate DNA repair. Using overexpression of
the Our coiled-coil region, we artificially ‘locked’ PALB2
in a PALB2–PALB2 state. Notably, this affected greatly
the ability of RAD51 to localize to DNA damage sites
suggesting that PALB2–PALB2 interactions are unfavor-
able for HR. Therefore, we suggest that in the absence of
DNA damage, PALB2 associates with itself and BRCA2
to sustain minimal HR. Following DNA damage, PALB2
dissociates and interacts with BRCA1 and BRCA2 to
form the BRCA1–PALB2–BRCA2 complex to allow: (i)
the localization of RAD51 at DSBs and, (ii) the stimula-
tion of RAD51 filament formation on ssDNA (Figure
6B). This is consistent with the observation that BRCA1
interacts more strongly with PALB2 after DNA damage
(Figure 5C). After RAD51 filament formation on resected
DNA DSBs, PALB2 and BRCA2 stimulate RAD51
during the invasion step of HR (20,21,24). This step
does not directly depend on PALB2 self-interaction as
in vitro recombination assays revealed that PALB21–40
showed similar activity than wild-type PALB2. Indeed,
in cells, PALB2 monomeric form is proficient for its lo-
calization to DSBs and to stimulate RAD51 foci forma-
tion. Subsequently, for the invasion step, only monomeric
PALB2 will be present at strand breaks to stimulate
RAD51 strand exchange activity.
In this study, we separated in vitro two functions of
PALB2 mediator activity: the stimulation of RAD51
filament formation which is strongly affected by PALB2
self-interaction and the stimulation of RAD51 for strand
invasion which functions independently of PALB2
self-interaction. Our model also speculates that the mo-
lecular switch between dimeric PALB2, which has
minimal activity, to monomeric PALB2 of enhanced
activity may be regulated by binding to other factors,
such as BRCA1. The BRCA1 phosphorylation on S988
by Chk2 is important for RAD51 foci formation and HR
activity (33,34). In a recent review, Powell and colleagues
propose that this phosphorylation on BRCA1 promotes
BRCA1–PALB2–BRCA2 complex formation [personal
communication and (35)]. Thus, by activating the forma-
tion of the BRCA1–PALB2–BRCA2 complex, phospho-
rylated BRCA1 may control a PALB2 molecular switch.
Furthermore, it has been shown recently that BRCA1 is
important for the activation of HR versus NHEJ by
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promoting ssDNA resection through limiting 53BP1
loading at the DSB (36,37). Consequently, the regulation
of PALB2 self-interaction in a BRCA1-dependent manner
could be another way for the cell to control the choice
between HR and NHEJ depending of its cell cycle state.
Altogether, our findings highlight a new mode of
PALB2 regulation for HR. This molecular switch may
prevent inappropriate recombination in normal conditions
and sustain DNA repair to the appropriate level when
cells are challenged with DNA damage.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online:
Supplementary Table 1 and Supplementary Figures 1–5.
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